Prime Medicine PRME
NASDAQ PRME
$4.30 +0.40 (+10.26%)
At close: Nov 11, 2026 · 4:00 PM EST

Prime Medicine (PRME) Gains from Sales and Divestitures (2023)

Updated

Prime Medicine's Gains from Sales and Divestitures was -$28,000 in Q4 2023.

Analysis

Prime Medicine (PRME) Gains from Sales and Divestitures (2023) Analysis & Trends

  • In earlier years, Gains from Sales and Divestitures was -$8,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Prime Medicine 704.88 Mn 469.45 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -28,000.00
API Access

Prime Medicine Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PRME&period=max&api_key=YOUR_API_KEY